Company Overview and News

10
What Is Going On At Axovant Sciences?

2018-08-15 seekingalpha - 2
On February 12, 2018, Axovant Sciences (AXON) issued a press release noting changes to the management team and Board of Directors. Dr David Hung retired as CEO and Dr Pavan Cheruvu took his place, among other changes. Three and a half months of radio silence followed. What broke the silence? Another press release on May 29 noting additions to the management team and organizational restructuring. Things got interesting on June 6, when AXON reported it had licensed a gene therapy for Parkinson’s disease from Oxford BioMedica and of course made additional management changes.
ACAD OXB OXBDF AXON

0
Market report: Shares struggle as sterling falls to lowest level since September

2018-08-06 telegraph.co.uk
Mounting fears in the City of a no-deal Brexit dragged the pound down to an 11-month low as the FTSE 100 stagnated amid heightened trade war worries.
OXB OXBDF JLIF

5
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis

2018-08-06 globenewswire
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis
IMDZ OXB OXBDF

7
Axovant Sciences Failed To Mention Critical Information

2018-07-15 seekingalpha - 2
On July 10th 2018 Axovant Sciences (AXON) announced a partnership with Benitec Biopharma (BNTC) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological disorders.
BLT OXB BNTC BNIKF OXBDF AXON BNTCW

7
Axovant, Benitec Gain on Licensing Deal for Gene Therapy

2018-07-10 zacks
Shares of Axovant Sciences (AXON - Free Report) gained after it announced a licensing agreement with Benitec Biopharma .
UNP BLT SLDB OXB BNTC BNIKF OXBDF AXON BNTCW

5
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders

2018-07-09 genengnews
Benitec Biopharma could generate up to $655 million-plus in payments from licensing its preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD; pictured), and five additional Benitec gene therapy candidates for neurological disorders to to Axovant Sciences. [NIH]
BLT OXB BNTC BNIKF OXBDF ONCE BNTCW AXON

5
Axonant Showing Signs Of A Comeback As FDA Increases Scrutiny Of Compounding

2018-07-06 seekingalpha
The overall bioscience market traded with a mixed sentiment for the day. Many equities under our coverage continued to log in further profits for investors.
OXB ESPR IBB XBI OXBDF ONCE AXON

216
Voyager's Parkinson's Gene Therapy Is Likely To Fail

2018-07-01 seekingalpha - 2
Voyager needs to raises money; it will most likely be an equity offering before phase 1b and phase 1 posterior trajectory data is released.
VYGR OXB OXBDF SNY AXON

217
Rounds Report: Axovant Rallied While The FDA Approved Epidiolex

2018-06-27 seekingalpha - 1
We look for a horse with one chance in two of winning and which pays you three to one. - Charlie Munger
DOVA GWPH OXB IBB XBI OXBDF ONCE GWP AXON

213
A Deep Dive Into Axovant's Parkinson's Gene Therapy

2018-06-25 seekingalpha - 2
Axovant will be initiating a clinical trial with a second-generation gene therapy AXO-Lenti-PD later this year.
OXB OXBDF AXON

213
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

2018-06-19 zacks - 1
Shares of Solid Biosciences Inc. (SLDB - Free Report) surged 10.9% after the company announced that the FDA has lifted the clinical hold on its phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001.
SLDB OXB OXBDF NEE AXON

215
Axovant's Parkinson's Gene Therapy Is Extremely Risky

2018-06-19 seekingalpha - 3
Axovant purchased an experimental Parkinson's gene therapy and is expected to start a clinical trial later this year.
ARNA OXB OXBDF AXON

217
Gene Therapy Prospects Make Axovant Sciences A Compelling Buy For 2018

2018-06-15 seekingalpha
Axovant Sciences' (AXON) licensing deal with Oxford BioMedica (OTCPK:OXBDF) is nothing short of a masterstroke. This deal has opened up the gene therapy segment for Axovant Sciences and has positioned the company to make a solid entry in the neurodegenerative disease segment. This transformation from being a small molecule player to a very potent lentiviral vector gene therapy company initially targeting Parkinson's disease or PD has been well received by the investor community.
OXB NVS OXBDF SNY AXON

370
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

2018-06-13 zacks - 2
The biotech sector was in focus last week with regular pipeline updates and collaboration/licensing deals. While biotech bigwig Amgen’s (AMGN - Free Report) drugs won both FDA and EC approvals, Axovant (AXON - Free Report) soared on a licensing deal Oxford BioMedica. Meanwhile, Regeneron (REGN - Free Report) collaborated with Zoetis to discover new veterinary treatments.
AMGN ALXN BIIB OXB OXBDF AXON

216
Axovant Sciences: Expect A Crash After An Overhyped Deal With Oxford BioMedica

2018-06-12 seekingalpha - 1
Axovant Sciences skyrocketed after a licensing agreement with Oxford BioMedica and investment by Roivant, resulting in a $373 million increase to its valuation.
IMDZ OXB LNSTY OXBDF AXON

Related Articles

REPH: Recro Pharma Analysis and Research Report

9h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

9h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

10h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: G6836F106